Profound Medical (TSE:PRN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Profound Medical has announced that its TULSA procedure will receive increased reimbursement under the new CMS rule, highlighting its advantage over other prostate treatment options. With a wider range of treatment settings and increased payment rates, TULSA is poised to redefine patient care with its incision-free approach.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.